Chongqing Genrix Biopharmaceutical Co., Ltd. Class ASSE: 688443

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Telikibart Injection for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults

Jul 17, 2026 · Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Telikibart Injection for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Withdrawal of Drug Registration ApplicationJul 1
Announcement on Voluntary Disclosure of the Approval for Market Launch of Siromivimab Injection for Passive Immunization Indication in Adults Exposed to Rabies VirusJun 23
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public OfferingJun 16

All Chongqing Genrix Biopharmaceutical Co., Ltd. Class A news releases